Please assess the completion status of the following clinical trial:

Trial Title: Impact of Renal SympAthetic DenerVation on Chronic HypErtension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 and ≤ 85 years of age.~* Refractory hypertension (per JNC-7, this is defined as BP ≥ 140/90 mmHg despite treatment with at least 3 anti-hypertensive drugs, at least one of which is a diuretic, or treatment by ≥ 4 anti-hypertensive drugs)~* Stable anti-hypertensive drug regimen, where no modifications have occurred for at least 2 weeks.~* Accessibility of renal vasculature.~* Ability to understand the requirements of the study.~* Willingness to adhere to study restrictions and comply with all post-procedural follow-up requirements.~Exclusion Criteria:~* Subject has a known secondary cause of hypertension.~* Subject has isolated White coat hypertension.~* Subject has Type 1 Diabetes.~* Subject has known significant renovascular abnormalities (e.g., significant renal artery stenosis, previous renal artery stenting or angioplasty that precludes the RSDN procedure because of no sites for ablation treatment, or the presence of an accessory renal artery in which the main renal artery is estimated to supply \<75% of the kidney )~* Significant renal artery stenosis is defined as \> 50% diameter stenosis on renal angiography. Per the guidelines for noninvasive vascular laboratory testing: a report from the American Society of Echocardiography and the Society for Vascular Medicine and Biology, significant renal artery stenosis is defined by any one of the following criteria on renal duplex ultrasound; i) Renal artery to aorta peak systolic velocity ratio ≥ 3.5; ii) Peak Systolic Velocity \> 200 cm/s with evidence of post-stenotic turbulence; iii) end diastolic velocity \>150 cm/s ; iv) Resistive Index (RI) \> 0.8; v) An occluded renal artery demonstrates no flow in the affected vessel.~* Subject has hemodynamically significant valvular heart disease for which reduction of blood pressure would be considered hazardous.~* Subject has New York Heart Association (NYHA) Class III or IV congestive heart failure, due to either systolic or diastolic dysfunction.~* Subject has an eGFR\<45 ml/min/1.73m2 (calculated by using the modified diet in renal disease (MDRD) formula), and is not receiving dialysis.~* Subject has orthostatic hypotension. (per the American Academy of Neurology/American Autonomic Society Conesus Statement, this is defined as a sustained reduction of systolic blood pressure of at least 20 mm Hg or diastolic blood pressure of 10 mm Hg within 3 min of standing or head-up tilt to at least 60° on a tilt table)~* Subject has a life expectancy \< 1 year for any medical condition.~* Subject is currently enrolled in another investigational drug or device trial that would interfere with this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Renal denervation group (Type: EXPERIMENTAL): Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).